Prevention of Seasonal Affective Disorder

GlaxoSmithKline300 enrolled

Overview

This is a placebo controlled study evaluating the effectiveness of medication in preventing depressive episodes in subjects with a history of Seasonal Affective Disorder (SAD).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

300

Conditions

Seasonal Affective Disorder

Interventions

Extended-release bupropion hydrochlorideDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient has a history of Major Depressive Disorder (MDD) with a seasonal pattern. Exclusion Criteria: * Patient has a current or past history of seizure disorder or brain injury. * Patient has a history or current diagnosis of anorexia nervosa or bulimia. * Patient has recurrent summer depression more frequently than winter depression. * Patient has primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), acute distress disorder, bipolar II disorder or other psychotic disorders. * Patient has initiated psychotherapy within the last 3 months.

Locations (51)

Outcomes

Primary Outcomes

Time between randomization and onset of a seasonal depressive episode. Proportion of depression-free subjects.

Secondary Outcomes

Change in HAMD-24 and -17 total score. Change in pain score.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.